Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants With Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

NCT07850453 is registered in ClinicalTrials.gov with Ribocure Pharmaceuticals AB as lead sponsor.

NCT NCT07850453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07850453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants With Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
Lead sponsor
Ribocure Pharmaceuticals AB
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
May 31, 2028
Enrollment
150 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pulmonary embolism (diagnosis), venous thromboembolism (vte)